P053

P053

P646221-5mg

5mg

≥97%

-20°C储存

超低温冰袋运输

P053 is a potent, non-competitive and selective ceramide synthase 1 ( CerS1 ) inhibitor wirh an IC 50 of 0.5 μM. P053 acts as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle. Whole-body adiposity regulator In Vitro P053 is the first isoform-specific ceramide synthase inhibitor. P053 inhibits CerS1 with nanomolar potency. P053 inhibits different human (h) or murine (m) CerS isoforms hCerS1, mCerS1, hCerS2, mCerS2, hCerS4, mCerS5, and hCerS6 with IC 50 s of 0.54±0.06, 0.46±0.08, 28.6±0.15, 18.5±0.12, 17.2±0.09, 7.2±0.10, and 11.4±0.17 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo P053 (5 mg/kg; administered daily by oral gavage; 7 days, in male C57BL6/J mice ) reduces C18 ceramide levels in skeletal muscle (SkM) . Daily P053 administration to mice fed a high-fat diet (HFD) increases fatty acid oxidation in skeletal muscle and impedes increases in muscle triglycerides and adiposity, but does not protect against HFD-induced insulin resistance . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL6/J mice Dosage: 5 mg/kg Administration: Oral gavage; daily Result: Reduced C18 ceramide levels in SkM by 31%, whereas 1 mg/kg/day had no effect. Form:Solid IC50& Target:IC50: 0.54±0.06 μM (hCerS1), 0.46±0.08 μM (mCerS1), 28.6±0.15 μM (hCerS2), 18.5±0.12 μM (mCerS2), 17.2±0.09 μM (hCerS4), 7.2±0.10 μM (mCerS5), 11.4±0.17 μM (hCerS6)

P053 是一种强效、非竞争性和选择性神经酰胺合成酶 1（CerS1）抑制剂，IC50 为 0.5u2009μM。P053 是肌肉线粒体脂肪酸氧化的内源性抑制剂。全身脂肪调节剂。

2748196-63-4

C18H21Cl2NO2

354.27 g/mol

OC[C@@](C)(N)CCC1=CC=C(OCC2=CC=C(Cl)C(Cl)=C2)C=C1

DMSO : 100 mg/mL (282.27 mM; ultrasonic and warming and heat to 60°C)